<DOC>
	<DOC>NCT00291226</DOC>
	<brief_summary>Glycine is a natural amino acid neurotransmitter that acts as a co-agonist at NMDA receptors in brain. We hypothesize that symptoms of the schizophrenia prodrome will improve with glycine to a greater degree than with placebo.</brief_summary>
	<brief_title>Glycine vs Placebo for the Schizophrenia Prodrome</brief_title>
	<detailed_description>A pilot clinical trial comparing glycine to placebo in patients with the schizophrenia prodrome.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>meet SIPS criteria for schizophrenia prodrome history of psychosis</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>schizophrenia prodrome</keyword>
</DOC>